Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.11.

Innate immune stimulation in development

Drug Class Route Company Clinical trial phase ClinicalTrials.gov identifier
GS9688 (Selgantolimod) TLR-8 agonist Oral Gilead Sciences, USA 2 NCT03491553/NCT03615066
RO7020531 (RG7854) TLR-7 agonist Oral Roche, Switzerland 2 NCT02956850/NCT03530917/NCT04225715